Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer’s (NYSE:PFE) respiratory syncytial virus (RSV) vaccine Abrysvo was well-tolerated and generated strong neutralizing ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year. Pfizer's vaccine against respiratory ...

Drug company Pfizer is seeking to expand the approval of its respiratory syncytial virus (RSV) vaccine to include adults over the age of 18.

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...